Michael Byrnes - 19 Feb 2024 Form 4 Insider Report for eFFECTOR Therapeutics, Inc.

Reporting relationship: Chief Financial Officer
Issuer ticker: N/A
Reported as of: 19 Feb 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Feb 2024, 17:02:32 UTC
Prior SEC filing: 16 Feb 2024
Next SEC filing: 27 Mar 2024
Source filing: View source filing
Reporting owner signature: /s/ Michael Byrnes

Key filing fact

Michael Byrnes filed Form 4 for eFFECTOR Therapeutics, Inc. on 21 Feb 2024.

Key facts

This page summarizes Michael Byrnes's Form 4 filing for eFFECTOR Therapeutics, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Feb 2024, 17:02.

Change

Previous filing in this sequence was filed on 16 Feb 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EFTR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +40,000
Change %
Price: $0.000000
Shares after: 40,000
Date: 19 Feb 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,000
Exercise price: $11.32
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of February 19, 2024 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date.